Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's...

|By:, SA News Editor

Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's confirmed with Aetna (AET -0.3%) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written.